secwatch.observer — SEC 8-K summary
======================================

Issuer:     Repare Therapeutics Inc. (—)
CIK:        0001808158
Form:       8-K
Filed at:   2025-12-29T23:59:59+00:00
Accession:  0001193125-25-332236
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Repare sells Polθ inhibitor RP-3467 to Gilead for up to $30M; Xeno deal per-share value rises to ~$2.20
--------------------------------------------------------------------------------

- Gilead will pay up to $30M ($25M upfront + $5M transfer completion) for Repare's RP-3467 Polθ ATPase inhibitor program.
- Repare retains other pipeline programs including RP-1664 and lunresertib/camonsertib.
- Estimated per-share cash payment in pending Xeno acquisition increased to ~$2.20, up from prior estimate due to Gilead upfront cash.
- Asset purchase closed Dec 23, 2025; consent obtained from NYU for assignment of related license agreement.
- CEO Steve Forte noted this is Repare's third and most significant portfolio transaction in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808158/000119312525332236/0001193125-25-332236-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808158/000119312525332236/d32279d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-332236

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer